DUBLIN–(BUSINESS WIRE)–The “Cell & Gene Therapy Manufacturing Service Market: Trends, Opportunities and Competitive Analysis 2023-2028” report has been added to ResearchAndMarkets.com’s offering.
The report provides valuable insights into the future of the cell & gene therapy manufacturing service market, presenting growth opportunities and competitive analysis.
The global cell & gene therapy manufacturing service market is expected to witness substantial growth in the coming years, driven by increasing demand in various areas such as cell processing, cell banking, process development, fill & finish operations, analytical and quality testing, raw material testing, and vector production. The market is projected to reach an estimated value of $20.5 billion by 2028, with a remarkable CAGR of 22.1% during the forecast period from 2023 to 2028.
Key market drivers include the rising number of cancer cases and rare diseases, as well as an increase in research and development spending by pharmaceutical companies.
Cell & Gene Therapy Manufacturing Service Market Segmentation:
The study provides a detailed analysis of the global cell & gene therapy manufacturing service market by therapy type, scale, mode, workflow, and region.
Cell & Gene Therapy Manufacturing Service Market by Therapy Type:
- Cell Therapy
- Stem Cell Therapy
- Non-Stem Cell Therapy
- Gene Therapy
Cell & Gene Therapy Manufacturing Service Market by Scale:
- Pre-Commercial/ R&D Scale
- Commercial Scale
Cell & Gene Therapy Manufacturing Service Market by Mode:
- Contract
- In-House
Cell & Gene Therapy Manufacturing Service Market by Workflow:
- Cell Processing
- Cell Banking
- Process Development
- Fill & Finish Operations
- Analytical and Quality Testing
- Raw Material Testing
- Vector Production
- Others
Cell & Gene Therapy Manufacturing Service Market by Region:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Key Companies in the Cell & Gene Therapy Manufacturing Service Market:
- Lonza
- Bluebird Bio
- Catalent
- Roche
- Samsung Biologics
Market Insights and Forecast:
The report predicts that cell therapy will continue to dominate the therapy type segment over the forecast period due to its increasing adoption in treating diseases such as cancer, autoimmune, urinary, and infectious issues.
Process development is expected to remain the largest segment due to the growing number of therapies progressing from clinical trials to regulatory approval.
North America is anticipated to be the largest region for the cell & gene therapy manufacturing service market, driven by an increasing number of gene and cell therapy research and development firms, along with a rise in the elderly population and cases of infectious diseases in the region.
Features of the Cell & Gene Therapy Manufacturing Service Market Report:
The report offers market size estimates, trend and forecast analysis, segmentation analysis, regional breakdown, growth opportunities, strategic analysis, and competitive intensity based on Porter’s Five Forces model.
Frequently Asked Questions (FAQs):
The report answers key questions related to the cell & gene therapy manufacturing service market, including market size, growth forecast, major drivers, key segments, prominent companies, future trends, and competitive threats.
For more information about this report visit https://www.researchandmarkets.com/r/b2p1dk
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900